YD Bio Limited (NASDAQ:YDES – Get Free Report) shot up 3.1% during mid-day trading on Wednesday . The stock traded as high as $3.32 and last traded at $3.0320. 22,050 shares were traded during mid-day trading, an increase of 76% from the average session volume of 12,558 shares. The stock had previously closed at $2.94.
Analyst Ratings Changes
Separately, Wall Street Zen raised YD Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Analysis on YDES
YD Bio Price Performance
Institutional Trading of YD Bio
An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC increased its holdings in YD Bio Limited (NASDAQ:YDES – Free Report) by 10.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,363 shares of the biotechnology company’s stock after purchasing an additional 5,292 shares during the quarter. Geode Capital Management LLC owned approximately 0.08% of YD Bio worth $711,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
YD Bio Company Profile
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
Recommended Stories
- Five stocks we like better than YD Bio
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for YD Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YD Bio and related companies with MarketBeat.com's FREE daily email newsletter.
